Belviq
23 June, 2023
Besponsa
23 June, 2023
Beovu
Label: Generic name
brolucizumab-dbll
Label: Drug class
Anti-angiogenic ophthalmic agents
Label: Dosage form
Intravitreal solution
Label: Route of administration
Intravitreal injection
Label: Dose
- Neovascular (Wet) Age-Related Macular Degeneration (AMD): 6 mg (0.05 mL) administered by intravitreal injection monthly for the first three doses, followed by 6 mg every 8 to 12 weeks.
- Diabetic Macular Edema (DME): 6 mg (0.05 mL) administered by intravitreal injection every six weeks for the first five doses, followed by 6 mg every 8 to 12 weeks.
Label: Mechanism of action
Brolucizumab is a humanized single-chain antibody fragment that binds to all isoforms of vascular endothelial growth factor A (VEGF-A), inhibiting its interaction with VEGF receptors VEGFR-1 and VEGFR-2. This inhibition suppresses endothelial cell proliferation, neovascularization, and vascular permeability, thereby reducing pathological angiogenesis and edema in the retina.
Label: Drug usage cases
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Diabetic Macular Edema (DME)
Label: Drug contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to brolucizumab or any of the excipients in BEOVU
Label: Side effects
- Blurred vision
- Cataract
- Conjunctival hemorrhage
- Vitreous floaters
- Eye pain
- Increased intraocular pressure
- Endophthalmitis
- Retinal detachment
- Retinal vasculitis
- Retinal artery occlusion
Label: Warnings
- Proper aseptic injection techniques must always be used when administering BEOVU to reduce the risk of endophthalmitis and retinal detachment.
- Monitor intraocular pressure (IOP) before, during, and after the injection. Acute increases in IOP have been observed within 30 minutes of intravitreal injection.
- Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
- There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors, including BEOVU. Monitor patients for signs and symptoms of arterial thromboembolic events.
Label: Use during pregnancy or breastfeeding
BEOVU has not been studied in pregnant women. It is not known whether brolucizumab is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BEOVU is administered to a nursing woman. The potential risks and benefits should be considered before administering BEOVU during pregnancy or breastfeeding.
